Emcure Pharmaceuticals (EMCURE) Stock Overview
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for EMCURE from our risk checks.
EMCURE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Emcure Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,880.20 |
| 52 Week High | ₹1,902.70 |
| 52 Week Low | ₹1,228.90 |
| Beta | 0 |
| 1 Month Change | 10.70% |
| 3 Month Change | 13.77% |
| 1 Year Change | 42.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.34% |
Recent News & Updates
Narrative Update • Jun 23
EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.Narrative Update • Jun 06
EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).Analysis Article • May 22
If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • May 03
EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).Recent updates
Narrative Update • Jun 23
EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.Narrative Update • Jun 06
EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).Analysis Article • May 22
If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • May 03
EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).Narrative Update • Apr 19
EMCURE: Upcoming Governance And Roche Agreement Will Shape Balanced Forward Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals slightly higher to around ₹1,796 from about ₹1,795, citing updated assumptions for revenue growth, profit margins and a modestly lower future P/E expectation. What's in the News Emcure signed a distribution agreement with Roche for select nephrology and transplant medicines in India, covering therapies for chronic kidney disease, anemia management, and transplant care, effective April 1, 2026 (Key Developments).Narrative Update • Apr 04
EMCURE: Upcoming Governance Decisions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margin and future P/E. This signals that their core view on the stock remains consistent.Narrative Update • Mar 21
EMCURE: Weight Management Franchise Will Support Future Upside Potential
Analysts have kept their price target for Emcure Pharmaceuticals steady at ₹1,794.83, citing essentially unchanged assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Emcure plans a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.Narrative Update • Mar 06
EMCURE: Weight Management Launch Will Underpin Future Shareholder Value Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794.83 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, which together support an unchanged price target narrative. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative Update • Feb 19
EMCURE: Weight Management Launch Will Support Stronger Long Term Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals higher from ₹1,688.50 to about ₹1,794.83, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E, which together support a slightly richer valuation framework. What's in the News Board meeting scheduled for Feb 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analysis Article • Feb 06
Here's Why We Think Emcure Pharmaceuticals (NSE:EMCURE) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Feb 05
EMCURE: Weight Management Launch And Alliance Will Shape Balanced Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals from ₹1,652.50 to ₹1,688.50, reflecting updated assumptions related to revenue growth, profit margins and a slightly lower future P/E multiple. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Analysis Article • Nov 14
Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...Analysis Article • Sep 27
These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...New Narrative • Aug 10
Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.Analysis Article • May 25
Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report
The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...Analysis Article • May 16
Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark
Emcure Pharmaceuticals Limited's ( NSE:EMCURE ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...Analysis Article • Feb 15
Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
The Emcure Pharmaceuticals Limited ( NSE:EMCURE ) share price has fared very poorly over the last month, falling by a...Analysis Article • Jan 06
We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Shareholder Returns
| EMCURE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.2% | 3.8% | 0.3% |
| 1Y | 42.6% | 11.8% | -0.7% |
Return vs Industry: EMCURE exceeded the Indian Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: EMCURE exceeded the Indian Market which returned -0.7% over the past year.
Price Volatility
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.5% |
Stable Share Price: EMCURE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: EMCURE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,731 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names.
Emcure Pharmaceuticals Limited Fundamentals Summary
| EMCURE fundamental statistics | |
|---|---|
| Market cap | ₹348.86b |
| Earnings (TTM) | ₹9.24b |
| Revenue (TTM) | ₹92.04b |
38.6x
P/E Ratio3.9x
P/S RatioIs EMCURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMCURE income statement (TTM) | |
|---|---|
| Revenue | ₹92.04b |
| Cost of Revenue | ₹36.57b |
| Gross Profit | ₹55.46b |
| Other Expenses | ₹46.22b |
| Earnings | ₹9.24b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 48.76 |
| Gross Margin | 60.26% |
| Net Profit Margin | 10.04% |
| Debt/Equity Ratio | 24.2% |
How did EMCURE perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 11:52 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emcure Pharmaceuticals Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | BOB Capital Markets Ltd. |
| Foram Parekh | BOB Capital Markets Ltd. |